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Abstract: We investigated the effects of rivastigmine (a cholinesterase inhibitor) and selegiline 
((-)deprenyl, an irreversible inhibitor of monoamineoxidase-B), alone and in combination, on 
brain acetylcholinesterase (AChE), (Na+, K+)-, Mg2+-ATPase activities, total antioxidant status 
(TAS), and learning performance, after long-term drug administration in aged male rats. The 
possible relationship between the biochemical and behavioral parameters was evaluated.
Methods: Aged rats were treated (for 36 days) with rivastigmine (0.3 mg/kg rat/day ip), 
selegiline (0.25 mg/kg rat/day im), rivastigmine plus selegiline in the same doses and way of 
administration as separately. Aged and adult control groups received NaCl 0.9% 0.5 ml ip.
Results: TAS was lower in aged than in adult rats, rivastigmine alone does not affect TAS, 
decreases AChE activity, increases (Na+, K+)-ATPase and Mg2+-ATPase activity of aged rat 
brain and improves cognitive performance. Selegiline alone decreases free radical production 
and increases AChE activity and (Na+, K+)-ATPase activity, improving cognitive performance 
as well. In the combination: rivastigmine seems to cancel selegiline action on TAS and AChE 
activity, while it has additive effect on (Na+, K+)-ATPase activity. In the case of Mg2+-ATPase 
selegiline appears to attenuate rivastigmine activity. No statistically signiﬁ  cant difference was 
observed in the cognitive performance.
Conclusion: Reduced TAS, AChE activity and learning performance was observed in old 
rats. Both rivastigmine and selesiline alone improved performance, although they inﬂ  uenced 
the biochemical parameters in a different way. The combination of the two drugs did not affect 
learning performance.
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Introduction
Brain aging in most cases is characterized by cognitive deﬁ  cits and a central cholinergic 
hypofunction (Bartus et al 1982). Alzheimer’s disease (AD), a neurodegenerative 
disorder, is characterized by loss of memory and other cognitive abilities. It is also 
characterized by a prominent loss of cholinergic neurons in the basal forebrain (Davis 
and Maloney 1976), leading to decreased amounts of acetylcholine and decreased 
activities of cholinacetyltransferase (ChAT) and acetylcholinesterase (AChE) in 
almost the entire neocortex (Coyle et al 1983). The observed association between the 
loss of cholinergic neurons, receptors, reduction of cholinergic markers, cognitive and 
executive function impairments in AD was the base for the development of cholinergic 
hypothesis (Bartus 2000) and the introduction of AChE inhibitors as the main 
therapeutic approach for this disease. Rivastigmine is a second-generation carbamate-
based pseudo-irreversible AChE and butyrylcholinesterase (BuChE) inhibitor, 
indicated for treatment of mild to moderate AD (Anand et al 1996; Corey-Bloom et al Neuropsychiatric Disease and Treatment 2008:4(4) 688
Carageorgiou et al
1998; Eskander et al 2005; Caltagirone et al 2005; Takeda 
et al 2006; Gonzalez-Gutierrez and Gobbart 2007) or for 
patients with rapid disease progression (Farlow et al 2005). 
As the disease and age progress, signiﬁ  cant loss of other 
neurons (noradrenergic, dopaminergic) is observed as well 
(Davies and Wolozin 1987; Strong 1998). The pathology of 
the disorder may involve oxidative stress and accumulation 
of free radicals, leading to excessive lipid peroxidation and 
neuronal degeneration in the brain (Smith et al 1991; Strong 
1998; Pratico and Delanty 2000). Selegiline,(-)deprenyl, 
an irreversible monoamineoxidase-B (MAO-B) inhibitor, 
has been used in depression and in Parkinson’s disease in 
combination with L-dopa (Birkmayer et al 1985; Lieberman 
and Fazzini 1991; Knoll 2000; Negrotti et al 2001; Kitani et al 
2002). Selegiline enhances the release of dopamine, blocks 
the reuptake of dopamine and produces an amphetamine-like 
effect (Ebadi et al 2002). Pretreatment with selegiline can 
protect neurons against a variety of neurotoxins as MPTP, 
DSP-4, 5,6-dihydroserotonin and AF64A, which damage 
dopaminergic, adrenergic, serotonergic, and cholinergic 
neurons respectively (Walsh et al 1984; Ricci et al 1992; 
Mayar and Haberle 1999; Matsubara et al 2001). In patients 
with moderate impairment from AD, treatment with 
selegiline slowed the progression of disease (Sano et al 1997; 
Filip and Colibas 1999; Knoll 2003). However, according 
to recent data from a meta-analysis, selegiline signiﬁ  cantly 
improved cognition and activities of daily living at an earlier 
time point, but not at a later assessment time (Wilcock et al 
2002; Birks and Flicher 2003). Selegiline prevents the effects 
of oxidative stress in a variety of models both in vitro and in 
vivo (Youdim et al 2001).
The underlying mechanism of the beneﬁ  cial effect of 
selegiline on neuronal function is believed to be associated 
with enhanced activity of free radical scavenging enzymes 
(Carrillo et al 1994; Kitani et al 2002; Kiray et al 2006), 
diminished production of hydrogen peroxide through MAO-
B inhibition (Cohen and Spina 1989; Takahata et al 2006), 
some trophic-like effects that increase the survival of degen-
erating motoneurons (Ju et al 1994), restoration of ChaT 
reduced activity (Koutsilieri 2001), the number of neurons 
in the hippocampus (Kiray et al 2006), or enhancement of 
neuroplastic status (Murphy et al 2006). Recently Ono and 
colleagues (2006) also reported an in vitro antiamyloidogenic 
activity of selegiline.
We have previously shown that the administration 
of selegiline in a dose of 0.25 mg kg-1 rat/other day for 
50 days in old rats increased whole brain TAS, stimulated 
(Na+, K+)-ATPase activity and although it increased AChE 
activity, it improved the learning performance of aged rats 
(Carageorgiou et al 2003).
The (Na+, K+)-ATPase, or Na+ pump, is an energy 
transducting ion pump ﬁ  rst described by Skou in 1952 
(Skou 1998). In recent years, research on (Na+, K+)-ATPase 
revealed that interactions of (Na+, K+)-ATPase with other 
proteins not only are important for regulation of pumping 
function, but also make it possible for the enzyme to func-
tion as a single transducter (Xie and Cai 2003). Long-term 
pharmacological interruption of cholinergic transmission can 
decrease the postsynaptic membrane potential by altering 
(Na+, K+)-ATPase activity. This can be seen as a decline in 
[3H] ouabaine binding (Henning et al 1994). Age-associated 
impairments in a test of attention and evidence of involvement 
of cholinergic systems was referred by Jones and colleagues 
(1995). It is known that inhibition of (Na+, K+)-ATPase 
induces neurotransmitter release in several experimental 
models (Rodríguez de Lores Arnaiz and Pellegrino de Iraldi 
1991). Furthermore, studies suggest that (Na+, K+)-ATPase 
might play a role on memory formation (dos Reis-Lunardelli 
et al 2007). According to Gorini and colleagues (2002) 
(Na+, K+)-ATPase is a particular age-related enzyme. The 
(Na+, K+)-ATPase activity is lower in all plasma membrane 
subfractions (rat frontal cerebral cortex) at 22 months of 
age, than in 5 months (where reduction is already evident at 
10 months of age). Similar reductions in (Na+, K+)-ATPase 
activity were observed by Kaur and colleagues (1998) in 
different brain regions of 24-month-old rats. However, old 
age and selective loss of cholinergic basal frontal cells did not 
signiﬁ  cantly alter the presynaptic second messenger system 
that inﬂ  uences (Na+, K+)-ATPase activity. On the other hand 
the lesions had a much greater effect on performance than 
old age alone did (Stoehr et al 1997).
Little is known about the activity of Mg2+-ATPase 
in old age, an enzyme that is of primary importance in 
phosphorylation reactions and the maintenance of high brain 
intracellular Mg2+. Its change can control rates of protein 
synthesis and growth of the cell (Sanui and Rubin 1982). 
Decreased Mg2+-ATPase activity in the frontal cortex of old 
age rats was reported by Gorini and colleagues (2002).
Oxidative stress has been implicated in aging and age-
related neurodegenerative diseases (Atamna and Frey 2007; 
Tahirovic et al 2007; Weinreb et al 2007) and the proposal of 
the “free radical theory of aging” (Harman 1956). Impaired total 
antioxidant capacity in different structures from aged rat brain 
was observed by Siqueira and colleagues (2005). A decrease 
of the total antioxidant status in the brain of old male rats has 
been observed by Carageorgiou and colleagues (2003).Neuropsychiatric Disease and Treatment 2008:4(4) 689
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Based on the aforementioned selegiline study in 
aged rats, the foreseen trend of combining drugs with a 
different mechanism of action in AD therapy (Youdim and 
Weinstock 2002; Ucar et al 2005; Dantoine et al 2006; 
Groner et al 2007; Tahirovic et al 2007) and since multiple 
factors contribute to AD pathology (van Dyck 2004; Liu 
and Ames 2005) we decided to investigate the effect of the 
combination of the two agents, rivastigmine and selegiline, 
on brain TAS, AChE, (Na+, K+)-ATPase, Mg2+-ATPase 
activities and on cognitive capacity of aged rats. We also 
considered evaluating the possibility of correlations between 
biochemical and behavioral data. It should be mentioned 
that there were no previous in vivo data about the effect of 
a) rivastigmine alone on the activities of brain (Na+, K+)-
ATPase, Mg2+-ATPase or TAS. and b) rivastigmine plus 
selegiline combined administration on all the biochemical 
and behavioral parameters studied.
Materials and methods
Animals
Fifty two (52) aged male Wistar rats (24 months old) and 
485 ± 23 g BW were used. A group of 11 adult rats (8 months 
old) and 391 ± 12 g BW was also used as an adult control. 
The rats were housed ﬁ  ve or six in a cage at a constant 
room temperature (22 ± 1 °C) under a 12-h light: 12-h dark 
(light 08:00–20:00 h) cycle. Food and water were provided 
ad libitum. Animals were cared for in accordance with the 
principles of the Guide for the Care and Use of Experimental 
Animals (Committee on Care and Use of Laboratory Animals 
1985).
Drugs in vivo administration
Rats were divided into ﬁ  ve groups, according to the procedure 
followed in the object recognition test: 1) Group (R) was 
treated with rivastigmine (0.3 mg kg−1 rat day-1 ip) for 
36 consecutive days, 2) Group (S) was treated with selegiline 
(0.25 mg kg−1 rat day−1 im) for the same period, 3) Group 
(R + S) was treated with the combination of the two drugs 
at the doses and way of administration mentioned before for 
each drug separately and for the same period of time, 4) a 
group was treated with equal volumes (0.5 ml) of NaCl 0.9% 
ip (aged control group) and 5) a group was also treated with 
equal volumes (0.5 ml) of NaCl 0.9% ip (adult control group) 
for every of the 36 consecutive days.
Tissue preparation
Animals were sacriﬁ  ced by decapitation (right after the 
last performance test and 90 minutes after the last drug 
administration) and the whole brain was rapidly removed. 
The tissue was homogenized and centrifuged as described 
earlier (Tsakiris et al 2000; Antoniades et al 2002). In the 
resulting supernatant, the protein content was determined 
according to the method of Lowry and colleagues (1951) and 
the enzyme activities and TAS were evaluated.
Determination of enzyme activities
AChE activity was determined according to Ellman and 
colleagues (1961) and (Na+, K+)-ATPase, Mg2+-ATPase 
activities according to Bowler and Tirri (1974). The enzyme 
reaction mixture and assay conditions of these enzyme activi-
ties were previously described in detail (Tsakiris et al 2000; 
Antoniades et al 2002).
Determination of brain total 
antioxidant status
TAS was evaluated in each fresh homogenized rat brain. The 
total antioxidant capacity was measured spectrophotometri-
cally by a commercial kit (Randox Laboratories Ltd., Cat. 
No. NX2332) as previously reported (Tsakiris et al 2000). 
2,2′-Azino-di-[3-ethylbenzthiazoline sulphonate] (ABTS) 
was incubated with a peroxidase (metmyoglobin) and H2O2 
in order to produce the radical cation ABTS+. The latter had 
a relatively stable blue-green color, which was measured at 
600 nm. Inhibited values of TAS reﬂ  ect the increase of brain 
free radical production whereas stimulated TAS values show 
the decrease of free radical production and the protective 
antioxidant effect of the drug in the brain.
Cognitive capacities tests
Cognitive capacities were evaluated using two different 
tasks: object recognition test (ORT) and passive avoidance 
conditioned response (PA). The ORT was carried out accord-
ing to the procedure described by Vannucchi and colleagues 
(Ennaceur and Delacour 1988; Scali et al 1994; Vannucchi 
et al 1997). The apparatus was an open white polyvinyl-
chloride arena (70 × 60 × 30 cm3) illuminated by a 75 W 
lamp suspended 50 cm above the arena. The objects to be 
distinguished were made of polyvinylchloride, grey-colored 
and were in two different shapes: cubes (8 × 8 cm2 side) or 
pyramids (8 cm height). Apparently they had no signiﬁ  cance 
for the rats. For the procedure, the rat was submitted to a ses-
sion of two trials, each of which had a 5-min duration. The 
intertribal interval (ITI) was 60 min. In the ﬁ  rst trial (T1) two 
identical objects were presented in two opposite corners of 
the box and the amount of time spent by each animal for the 
object exploration was recorded. Exploration was considered Neuropsychiatric Disease and Treatment 2008:4(4) 690
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to be directing the nose at a distance 2 cm to the object 
and/or touching it with the nose. During the second trial 
(T2), one of the objects presented in T1 was replaced by a 
new (differently-shaped) one. To reduce place preference 
effects, the positions of the two different objects were ran-
domly changed during T2 for each rat. The times spent on 
exploration of the familiar (F) and new (N) object during T2 
were recorded separately and a discrimination index (D) was 
calculated (N - F/N + F). An animal was deﬁ  ned as impaired 
if the D was 0.20. This procedure took place twice for each 
animal. The ﬁ  rst session was one day before the beginning 
of drugs administration. Among the 52 aged rats studied, 
42 (81%) showed impaired performances with a D 0.10, 
four rats were unimpaired (D 0.50), while six rats were 
discarded because they did not explore. The 42 impaired aged 
rats were subdivided into the four aforementioned groups: 
Aged control group (10 rats), Group (R) (10 rats), Group (S) 
(11 rats), and Group (R + S) (11 rats). Among the 11 adult 
rats studied none was discarded, as all of them sufﬁ  ciently 
explored. The second session was on the 34th day of the drugs 
administration, in order to evaluate the cognitive capacity of 
the animals practically at the end of the experiment. The task 
took place one hour after the drugs’ administration.
The passive avoidance training was started 24 h after the 
last object recognition session. It was carried out according 
to the procedure described by Riekkinen and colleagues 
(1997) with some modiﬁ  cations (the testing trial took place 
24 h after the training trial and not 72 h after it) and consisted 
of two trials. The passive avoidance box had a light and a 
dark compartment of equal size, which were separated by a 
sliding guillotine door. During the ﬁ  rst trial (training trial), 
which took place at the 35th day of drugs administration, the 
rats were placed in the light compartment. Thirty seconds 
later the door was opened. After the rat entered the dark 
compartment, the door was closed and a foot shock of 1.0 mA 
(3 s) was given. The latency to enter the dark compartment 
was measured (360 s maximum latency). During the second 
trial (testing trial), which took place on the 36th day of drugs 
administration (last day of the experiment), the rat was placed 
in the light compartment again and the latency to enter the 
dark compartment was measured. Passive avoidance most 
likely involves both working memory and reference memory 
(Myhrer 2003).
Statistical analysis
The biochemical data were analyzed by a two-tailed Student’s 
t-test. The object recognition data were analyzed by a non-
parametric Mann-Whitney test and the passive avoidance 
data were analyzed by an one-way ANOVA test and a 
post-hoc test (Bonferroni test).
Drugs
Rivastigmine; Novartis Ltd., Basle, Switzerland. Selegiline; 
Sigma-Aldrich. St. Louis, MO, USA.
Results
Total antioxidant status (TAS)
Group (S) (received selegiline) showed a signiﬁ  cant increase 
in TAS compared with the control group of aged rats (+30%, 
P  0.001, tvalue = 9.66). Groups (R) (received rivastigmine) 
and (R + S) (received rivastigmine + selegiline) did not 
show any difference in comparison to the aged control group 
(tvalues = 0.48 and 1.13 respectively). TAS was signiﬁ  cantly 
decreased in rivastigmine + selegiline-treated rats compared 
with selegiline-treated rats (-21%, P  0.001, tvalue = 16.66) 
(Figure 1).
Brain AChE activity
Selegiline-treated rats revealed a signiﬁ  cant increase in 
brain AChE activity compared with the aged control rats 
(+25%, P  0.001, tvalue = 10.73). Contrary to this, rivastig-
mine alone and rivastigmine+selegiline co-administration 
induced a signiﬁ  cant decrease in brain AChE activity in 
comparison to the aged saline-treated rats (−20%, P  0.001, 
tvalue = 10.80 and −22%, P  0.001, tvalue = 11.08, respectively). 
Brain AChE activity was also signiﬁ  cantly decreased in rats 
treated with rivastigmine+selegiline in comparison to the rats 
treated with selegiline alone (-38%, P  0.001, tvalue = 36.99) 
(Figure 2).
(Na+, K+)-ATPase activity
(Na+, K+)-ATPase activity was signiﬁ  cantly increased in 
rats which received selegiline (+50%, P  0.001, tvalue = 
11.08) or rivastigmine (+36%, P  0.001, tvalue = 8.48) in 
comparison with aged saline-treated rats. Furthermore, in 
the case of rivastigmine+selegiline co-administration, an 
additive action of the two drugs concerning the increase of 
(Na+, K+)-ATPase activity was revealed in comparison to 
the aged control group (+88%, P  0.001, tvalue = 15.62). A 
signiﬁ  cant increase of (Na+, K+)-ATPase activity in (R+S) 
group in comparison to the (S) group was also observed 
(+25%, P  0.001, tvalue = 14.84) (Figure 3).
Mg2+-ATPase activity
Mg2+-ATPase activity was significantly increased in 
(R) group and (R + S) group in comparison to the aged Neuropsychiatric Disease and Treatment 2008:4(4) 691
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Figure 1 Effects of rivastigmine, selegiline, and rivastigmine + selegiline on brain antioxidant status (TAS). TAS values were determined in each homogenized rat whole brain. 
Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult 
control rats, of selegiline, and of rivastigmine + selegiline indicate the mean ± SE. of eleven independent experiments (eleven rats). The average value of each experiment arises 
from three determinations.
Notes: NS, nonstatistical signiﬁ  cance; ***P  0.001 compared with aged control group; ###P  0.001 compared with selegiline-treated group.
Figure 2 Effects of rivastigmine, selegiline, and rivastigmine + selegiline on brain AChE activity.   AChE activities were determined in each homogenized rat whole brain. Values 
of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of adult control 
rats, of selegiline and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats). The average value of each experiment arises from 
three determinations.
Notes: ***P  0.001 compared with aged control group; ###P  0.001 compared with selegiline-treated group.
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control group (+40%, P  0.001, tvalue = 8.78 and +23%, 
P  0.001, tvalue = 8.15, respectively), while no difference 
in Mg2+-ATPase activity was observed in the selegiline-
treated group(tvalue = 0.55). The rivastigmine+selegiline co-
administration induced a signiﬁ  cant increase in Mg2+-ATPase 
activity in comparison to selegiline alone administration 
(+26%, P  0.001, tvalue = 13.45) (Figure 4).
Object recognition test
In the object recognition test the discrimination between familiar 
and novel objects was signiﬁ  cantly better in selegiline-treated 
(P  0.001, Mann-Whitney U = 4.50) or rivastigmine-treated 
rats (P  0.001, Mann-Whitney U = 0.50) than aged saline-
treated rats. There was no statistically signiﬁ  cant difference 
in the discrimination index between (R + S) group (Mann-
Whitney U = 12.00) and aged control group (Figure 5).
Passive avoidance procedure
In passive avoidance procedure, during the training trial the 
mean latency (42 s) was not signiﬁ  cantly different among 
the groups. During the testing trial, a signiﬁ  cantly better 
performance was observed in groups (R)(F = 59.18) and 
(S)(F = 59.18), in comparison with the aged control group. 
The combination of rivastigmine + selegiline did not show 
any statistically signiﬁ  cant difference from the aged control 
group (F = 59.18) (Figure 6). These results are similar to 
those of the object recognition test.
Adult versus aged rats
An increase of total antioxidant status (TAS) was observed 
in adult control group compared with the aged control group 
(+20%, P  0.001, tvalue = 5.62) (Figure 1). Adult controls 
revealed a significant increase in brain AChE activity 
compared with the aged control rats (+39%, P  0.001, 
tvalue = 25.07) (Figure 2). (Na+, K+)-ATPase activity was sig-
niﬁ  cantly decreased in adult controls compared to the aged 
control group (−24%, P  0.001, tvalue = 5.17) (Figure 3). 
Mg2+-ATPase activity was signiﬁ  cantly increased in adult 
control group in comparison with the aged control group 
(+34%, P  0.001, tvalue = 10.69) (Figure 4). In the object 
recognition test the adult control group performed signiﬁ  -
cantly better than the aged one (P  0.05, Mann-Whitney 
U = 9.00) (Figure 5). In passive avoidance procedure, during 
the testing trial, a better performance was observed in adult 
control group in comparison with the aged control group 
(F = 59.18) (Figure 6).
Figure 3 Effects of rivastigmine, selegiline, and (rivastigmine + selegiline) on brain (Na+, K+)-ATPase activity. (Na+, K+)-ATPase activities were determined in each homogenized rat 
whole brain. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups 
of adult control rats, of selegiline and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats). The average value of each experiment 
arises from three determinations.
Notes: ***P  0.001 compared with aged control group; ###P  0.001 compared with selegiline-treated group.
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Discussion
We have examined: (a) the long term effects of rivastigmine 
in combination with selegiline on the activity of AChE, (Na+, 
K+)-ATPase, Mg2+-ATPase and TAS in whole brain homog-
enate of aged male rats, as well as their cognitive capacity; 
and (b) the possible relationship between biochemical and 
behavioral ﬁ  ndings.
Rivastigmine decreased AChE activity in the aged rat 
whole brain as expected (Anand et al 1996; Corey-Bloom 
et al 1998), in comparison with the adult and aged control 
group (Figure 2). It is worth noticing that the adult control 
has the highest value of AChE activity. On the contrary, 
selegiline alone signiﬁ  cantly increased AChE activity in the 
aged rats. The latter data are in accordance with other stud-
ies (Ricci et al 1992; Lakshmana et al 1998; Zhu et al 2000; 
Carageorgiou et al 2003). In particular Zhu and colleagues 
(2000) found increased AChE activity in the rat brain fol-
lowing 1 week of selegiline administration and Lakshmana 
and colleagues (1998) observed increased AChE activity in 
certain brain areas of adult monkeys following selegiline 
treatment with most pronounced effect in the region of 
hippocampus. Enhanced AChE activity in rat hippocampus 
was also reported by Ricci and colleagues (1992) following 
intracerebroventricular administration of selegiline. In the 
combination of rivastigmine + selegiline, the rivastigmine 
effect appears to prevail leading to a signiﬁ  cant decrease in 
brain AChE activity compared with the (S) group and with 
the two control groups (Figure 2).
Brain Mg2+-ATPase activity
0
2
4
6
8
10
12
14
M
g
2
+
-
A
T
P
a
s
e
a
c
t
i
v
i
t
y
(
μ
m
o
l
P
i
/
h
x
m
g
p
r
o
t
e
i
n
)
aged control
n=10
adult control
n=11
rivastigmine
n=10
selegiline
n=11
rivastigmine+
selegiline
n=11
   ***
    ***
   ***
 ###
NS
Figure 4 Effects of rivastigmine, selegiline, and (rivastigmine + selegiline) on brain Mg++-ATPase activity. Mg++-ATPase activities were determined in each homogenized rat whole 
brain. Values of the groups of aged control rats and of rivastigmine indicate the mean ± standard error (SE) of ten independent experiments (ten rats). Values of the groups of 
adult control rats, of selegiline and of rivastigmine + selegiline indicate the mean ± SE of eleven independent experiments (eleven rats). The average value of each experiment 
arises from three determinations.
Notes: NS, nonstatistical signiﬁ  cance; ***P  0.001 compared with aged control group; ###P  0.001 compared with selegiline-treated group.
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Reduced activity of AChE and ChAT has been reported 
in the cortex and the hippocampus of AD patients (Fishman 
et al 1986) and is also associated with the decline in cognitive 
function (DeKosky et al 1992). In our study, brain AChE 
activity was decreased in aged rats, in parallel with the 
object recognition and passive avoidance performance 
(Figure 2, 5–6). On the contrary, while rivastigmine (as 
expected) decreases AChE activity, it improves cognitive 
performance. Here a question could arise as to whether the 
20% inhibition of AChE by rivastigmine is enough to produce 
an increase in cortical and hippocampal ACh release. Many 
studies in the literature using different doses of rivastigmine 
revealed a strong correlation between AChE inhibition and 
ACh increase in the aforementioned rat brain areas (Tanaka 
et al 1994; Chen et al 1998; Kozaka 1999; Trabace et al 
2000; Scali et al 2002; Amenta et al 2006; Liang and Tang 
2006). Considering the improved performance in learning 
and memory tests by rivastigmine group of rats, we suggest 
that this percentage reduction of AChE was enough for the 
needed cortical and hippocampal ACh release. Also, while 
selegiline increases AChE activity, it improves cognitive 
performance. In the combination of rivastigmine + selegiline 
treatment no improved performance was observed despite 
decreased AChE activity. Concerning AChE activity, it is 
obvious that the mechanism by which a better performance 
is attained in the behavioral tests following administration 
of rivastigmine or selegiline (given separately) is different. 
Rivastigmine is used in AD according to the cholinergic 
hypothesis, which improves or delays to some extent the 
deterioration of AD patients (Anand et al 1996; Corey-Bloom 
et al 1998; Bartus 2000). At the same time selegiline was 
found to improve cognitive function after long-term adminis-
tration in rats (Knoll 2000) and to slow the progression of AD 
in man (Sano et al 1997). In our past experiments, although 
selegiline increased AChE activity, it improved avoidance 
performance (Carageorgiou et al 2003). The present study 
also shows improvement in both learning parameters. One 
can only speculate that the increased expression of ChAT 
and AChE in the hippocampus by selegiline (Ricci et al 
1992) may have also caused an increase of ACh (which 
is mainly involved in learning and memory) provided that 
ACh release is not affected by selegiline in the hippocampus 
(Knoll 1989; Nowakowska et al 2001; de Lima et al 2005). 
Furthermore, it has been reported that increases in dopamine 
levels enhance a compensatory release of acetylcholine in 
the frontal cortex (Nilsson et al 1992; Shimazu et al 1996) 
and that the forebrain dopaminergic system is related to 
cognitive function (Marie and Defer 2003; Remy and Samson 
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2003). According to Koutsilieri and colleagues (2001) 
selegiline (given in a dose of 2 mg/kg) completely restores 
ChAT activity deﬁ  cits in simian immunodeﬁ  ciency infec-
tion in brain regions containing cholinergic neurons. It is 
unclear whether selegiline acted on the expression of ChAT 
(directly or through increased dopamine availability) thereby 
increasing protein synthesis or as a neuroprotective agent on 
cholinergic and other neurons through its antioxidant effects 
(Kitani et al 2002). In addition, Appleyard (1995) reported 
that AChE induced long-term potentiation in hippocampal 
pyramidal neurons, suggesting that AChE per se might 
enhance cognitive performance. We could refer to Shen´s 
(1994, 2004) hypotheses on the design of agents that could 
enhance the neuronal AChE activity in order to delay the 
degeneration of brain AChE system in the development of 
dementia and AD. Furthermore, Frolich (2002) has come to 
a similar conclusion concerning the cholinergic hypothesis 
in its present form and the use of AChE-inhibitors. Accord-
ing to Kaduszkiewicz and colleagues (2005), the scientiﬁ  c 
basis for recommendations of cholinesterase inhibitors for the 
treatment of Alzheimer´s disease is questionable because of 
ﬂ  awed methods and small clinical beneﬁ  ts; even though the 
AChE inhibitors and memantine is the only available drug 
treatment until now (Lane 2006; Birks 2006).
In any case, one cannot exclude the neuronal adaptations 
to diminished synaptic ACh metabolism in acetylcholines-
terase knockout mice (Volpicelli-Daley et al 2003) and the 
possibility of AChE involvement of the senile plaque (Rees 
and Brimijoin 2003; Castro and Martinez 2006).
The synaptic plasma membrane enzyme (Na+, K+)-
ATPase is very important for neurotransmission-neuronal 
excitability (Sastry and Philips 1977), metabolic energy 
production (Mata et al 1980), the uptake and release of cat-
echolamines (Bogdanski et al 1968; Swann 1984), serotonin 
(Hernandez 1987), glutamate (Lees et al 1990), and at least 
partial ACh release (Meyer and Cooper 1981). Studies sug-
gest that (Na+, K+)-ATPase might play a role on memory 
formation (dos Reis-Lunardelli et al 2007) and that it is a 
particular age-related enzyme (Gorini et al 2002).
Increased activity of whole brain (Na+, K+)-ATPase was 
observed after the administration of rivastigmine, selegiline, or 
their combination (Figure 3). In the latter, the effect seems to be 
additive. Similar results concerning increased enzyme activity 
in aged and selegiline-treated rats were observed in our previous 
studies (Tsakiris et al 1996; Carageorgiou et al 2003).
Dickey and colleagues (2005) reported a decreased 
overall (Na+, K+)-ATPase enzyme activity in the amyloid 
containing hippocampi of the APP + PSI mice. They also 
reported absence of (Na+, K+)-ATPase staining in the zone 
surrounding congophilic plaques, which was occupied by 
dystrophic neurites and that cerebral (Na+, K+)-ATPase can 
be directly inhibited by high concentrations of soluble Ab. It 
has been also reported that (Na+, K+)-ATPase protein levels 
are decreased in AD tissue but not in normal aged tissue 
(Harik et al 1989; Liguri et al 1990). Our study deals with 
normally aged rats in which (Na+, K+)-ATPase activity was 
actually and signiﬁ  cantly increased in comparison with the 
adult control, but their performance was decreased. Consid-
ering that ouabain, a (Na+, K+)-ATPase inhibitor, has been 
shown to impair memory consolidation, it was suggested that 
increasing (Na+, K+)-ATPase activity and maintaining ionic 
balance of the neurons may beneﬁ  t AD patients by delaying 
the onset of neuritic dystrophia and memory dysfunction 
(Watts and Mark 1971; Mark and Watts 1971).
In our study with aged rats, in spite of enhanced (Na+, K+)-
ATPase activity in comparison with the adult control, the aged 
animals had an impaired learning performance. In addition, 
in the (S) and (R) groups (with enhanced (Na+, K+)-ATPase 
activity) a better learning performance was observed, while in 
the combination group (in which an even higher increase of (Na+, 
K+)-ATPase activity was observed) no statistically signiﬁ  cant 
difference in its learning performance was noticed (Figures 3, 
5–6). According to all the above, we come to the conclusion 
that increased (Na+, K+)-ATPase activity is not relevant to the 
cognition enhancement by rivastigmine, selegiline, or their 
combination, at least not under our experimental conditions.
The role of Mg2+-ATPase is to maintain high brain 
intracellular Mg2+, the changes of which can control rates 
of protein synthesis and growth of the cell (Sanui and Rubin 
1982). Decreased Mg2+-ATPase activity in the frontal cor-
tex of old age rats was reported by Gorini and colleagues 
(2002). In our experiments, decreased Mg2+-ATPase activity 
was observed in old rats in parallel with decreased learning 
performance. Mg2+-ATPase activity was found to be higher 
in the groups (R), (R+S) and young controls (Figure 4). 
Consequently, a positive association between increased 
Mg2+-ATPase activity and learning performance could 
be supported for rivastigmine, while selegiline improves 
learning performance without affecting brain Mg2+-ATPase 
activity. In the combination, although there was an increased 
Mg2+-ATPase activity, no signiﬁ  cant improvement in the 
behavioral parameters was observed. It is likely that the 
addition of selegiline in some way reduced the effect of 
rivastigmine alone on Mg2+-ATPase activity and this could 
inﬂ  uence the better performance of rivastigmine alone. This 
association is questionable as well.Neuropsychiatric Disease and Treatment 2008:4(4) 696
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The observed decrease of brain TAS during aging is 
in accordance with our previous studies (Tsakiris et al 
1996; Carageorgiou et al 2003) and is associated with the 
decreased learning performance (object recognition and pas-
sive avoidance test) (Figures 1, 5–6). Although rivastigmine 
administration in aged rats did not affect TAS, it resulted in 
a better learning performance. On the contrary, selegiline 
administration (as previously shown by Carageorgiou and 
colleagues [2003]) increased TAS and this effect can be 
linked with better learning performance (Figures 1, 5–6). 
Similar results were also reported by Kiray and colleagues 
(2006): increase of spatial memory performance in aged male 
rats after selegiline administration for 21 days, suppression of 
lipid peroxidation, and alleviation of the age-related decrease 
of the number of neurons in the hippocampus. Improved 
performance after long term selegiline administration has 
also been observed by Knoll (1989) and other investigators 
(Nowakowska et al 2001; de Lima et al 2005). In the combi-
nation of rivastigmine + selegiline no statistically signiﬁ  cant 
differences were observed either in TAS or in learning perfor-
mance although there is a tendency in the object recognition 
test (Figures 1, 5). It is rather obvious that selegiline effect on 
TAS is blunted by rivastigmine (Figures 1, 5–6). Selegiline is 
a MAO-B inhibitor enhancing dopamine levels and after its 
chronic administration long-term postsynaptic changes have 
most likely occurred. The dopaminergic activity for example 
could be inhibitory to cholinergic striatal inter neurons. This 
probably explains the negation of the behavioral effects of 
rivastigmine by selegiline. In the study of Sagi and colleagues 
(2005) the chronic treatment of rats with ladostigil, a novel 
drug derived from the combination of rivastigmine and a 
MAO-B inhibitor rasagiline, resulted in activation of both 
striatal cholinergic and dopaminergic activity, attenuation 
of stereotyped motor behavior and maintenance of normal 
spontaneous motor performance. However, Takahata and 
colleagues (2005) (donepezil and selegiline in acute and high 
dose in scopolamine + chlorophenylalanine – induced mem-
ory deﬁ  cits) and Dringenberg and colleagues (2000) (tacrine 
and selegiline with electroencephalographic and behavioral 
evidence) who used totally different experimental protocols 
observed that the combination of selegiline and another 
AChE inhibitor (donepezil or tacrine) acted synergistically 
and improved reversal of memory impairment in rats.
Conclusions
The overall analysis of our data revealed that rivastigmine 
when given alone decreases AChE, does not inﬂ  uence TAS, 
increases (Na+, K+)-ATPase and Mg2+-ATPase activities, 
and improves learning performance of the aged rats. In the 
combination the effect of rivastigmine on AChE activity 
(reduced) appears to prevail that of selegiline (increased) 
and the result is reduced activity of AChE. In the case of 
TAS, although rivastigmine when given alone, did not 
affect TAS, in the combination decreases the enhanced by 
selegiline old rat brain TAS and increases Mg2+-ATPase 
activity. There is also an improved learning performance by 
each drug alone, but not in the combination. It is obvious 
that the better performance of rivastigmine and selegiline 
given separately in the object recognition and in the pas-
sive avoidance test is attributed to a different mechanism 
of action: Selegiline possibly acts through its antioxidant 
effect and increased levels of catecholamines and rivastig-
mine by its anticholinesterase activity and increased levels 
of acetylcholine. Finally, the combination of the two drugs 
does not appear to be beneﬁ  cial for the declining memory 
of aged rats at least not under our experimental conditions. 
Reduced Mg2+-ATPase activity is correlated with old age and 
reduced learning performance. Rivastigmine is correlated 
with increased Mg2+-ATPase activity and increased learning 
performance. Decreased TAS is correlated with old age and in 
parallel with decreased performance. Selegiline is correlated 
with increased TAS and increased performance. In the com-
bination, rivastigmine+selegiline did not affect either TAS 
or learning performance. Several transmitter systems can 
probably have a primary function in some cognitive processes 
and among which are the cholinergic and dopaminergic ones, 
but the extent of interactions is difﬁ  cult to be elucidated. The 
subject therefore requires further investigation.
To our knowledge this is the ﬁ  rst report about a) the 
effect of rivastigmine on (Na+, K+)-ATPase and Mg2+-ATPase 
activities, TAS, on rat whole brain and b) the combined 
administration of rivastigmine and selegiline and its effect 
on all the studied parameters.
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